Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVB-S6-500 plus paclitaxel in platinum-resistant recurrent ovarian cancer (Phase 3)
2021-000293-28Phase 3Terminated
- Sponsor
- Aravive, Inc.
- Start
- Jun 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Batiraxcept + paclitaxel with Placebo + paclitaxel (2 arms). Primary endpoint: Progression-free survival. Started Jun 2021; status: terminated.
02
Drugs
batiraxcept
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2021-000293-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000293-28.